Potent antagonist of L-AP4-induced effects in rat spinal cord, thalamic and hippocampal neurons, showing selectivity over (1S,3S)-ACPD-induced effects. Potent antagonist of mGlu receptors linked to adenylyl cyclase in adult rat cortical slices.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 245.17. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.08 mL||20.39 mL||40.79 mL|
|5 mM||0.82 mL||4.08 mL||8.16 mL|
|10 mM||0.41 mL||2.04 mL||4.08 mL|
|50 mM||0.08 mL||0.41 mL||0.82 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71 PMID: 8864696
Bushell et al (1996) Pharmacological antagonism of the actions of group II and group III mGluR agonists in the lateral perforant path of rat hippocampal slices. Br.J.Pharmacol. 117 1457 PMID: 8730739
Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851 PMID: 8532166
Salt and Turner (1996) Antagonism of the presumed presynaptic action of L-AP4 on GABAergic transmission in the ventrobasal thalamus by the novel mGluR anatagonist MPPG. Neuropharmacology 35 239 PMID: 8734494
If you know of a relevant reference for MPPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MPPG, supplier, Group, III, group, II, mGlur, antagonists, selective, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, Glutamate, (Metabotropic), Group, III, Receptors, Glutamate, (Metabotropic), Group, III, Receptors, Tocris Bioscience
1 Citation for MPPG
Citations are publications that use Tocris products. Selected citations for MPPG include:
Dobson et al (2015) Caffeine Modulates Vesicle Release and Recovery at Cerebellar Parallel Fibre Terminals, Independently of Calcium and Cyclic AMP Signalling. Mol Cancer Res 10 e0125974 PMID: 25933382
Do you know of a great paper that uses MPPG from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.